China’s Burning Rock Biotech completes Series C financing of RMB 850 million

China’s Burning Rock Biotech completes Series C financing of RMB 850 million

Burning Rock Biotech, which was founded in 2014 and focuses on NGS (Next-Generation Sequencing) diagnostics solutions for precision medicine in oncology, today announced the closing of the Series C financing totaling RMB 850 million. The financing was led by GIC, followed by LYFE Capital, CMB International Capital, Lilly Asia Ventures (LAV), Sequoia Capital China and T&Brothers Capital.